Literature DB >> 2583860

Expression of the pS2 gene in normal, benign and neoplastic human stomach.

Y Luqmani1, C Bennett, I Paterson, C M Corbishley, M C Rio, P Chambon, G Ryall.   

Abstract

The expression of the estrogen-regulated breast-cancer-associated pS2 gene was examined in 75 stomach resections taken from 45 patients. The 600-base pS2 mRNA was found in all of the 47 non-neoplastic samples at varying levels: in the histologically normal group we observed a Poisson-type distribution, whereas 79% of the tissues exhibiting dysplastic features expressed high levels of transcript. Tumour samples expressed relatively lower pS2 mRNA, with only 18% having high levels and 43% with no detectable expression. These differences were not correlated to tumour grading, stage or site. No amplification or rearrangement of the pS2 gene was found. Immunohistochemical analysis of formalin-fixed paraffin sections, using a polyclonal antibody against pS2 protein, showed specific staining of both cytoplasm and membrane of epithelial cells in the neck region of antral and body glands as well as in luminal secretions. Immunoreactivity was observed in the sub-nuclear region of foveolar cells, with specialized gland and goblet cells in atrophic gastritis being negative. Heterogeneous but strong focal cytoplasmic staining was seen in tumour cells as well as in dysplastic epithelium. Two gastric cell lines, KATO III and MKN-45, derived from poorly differentiated adenocarcinomas also expressed pS2, whereas 3 other lines from well differentiated parental tumours did not. Genomic analysis revealed a BamHI polymorphism in Kato III cells and in the non-expressing MKN-28 cells. Immunostaining to pS2 protein was also demonstrated in the cytoplasm of KATO III cells, but neither these nor any of 30 tissues examined showed any positivity with a monoclonal antibody (MAb) to estrogen receptor. Our results suggest that pS2 is normally expressed in human stomach, possibly in association with secretory activity, and becomes down-regulated during malignancy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2583860     DOI: 10.1002/ijc.2910440510

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

Review 1.  Trefoil peptides.

Authors:  W M Wong; R Poulsom; N A Wright
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

2.  Altered expression of TFF-1 and CES-2 in Barrett's Esophagus and associated adenocarcinomas.

Authors:  Charles A Fox; Lisa M Sapinoso; Hong Zhang; Wanghai Zhang; Howard L McLeod; Gina R Petroni; Tarun Mullick; Christopher A Moskaluk; Henry F Frierson; Garret M Hampton; Steven M Powell
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

3.  Trefoil factor family-3 is associated with aggressive behavior of colon cancer cells.

Authors:  Xianyang Yio; Jie-yu Zhang; Mark Babyatsky; Anli Chen; Jing Lin; Qui-Xiang Fan; J Lawrence Werther; Steven Itzkowitz
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

4.  Differential expression of oestrogen receptor and oestrogen inducible genes in gastric mucosa and cancer.

Authors:  S Singh; R Poulsom; N A Wright; M C Sheppard; M J Langman
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

5.  A second trefoil protein, ITF/hP1.B, is transcribed in human breast cancer.

Authors:  B Theisinger; G Seitz; S Dooley; C Welter
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 6.  GATA factors in gastrointestinal malignancy.

Authors:  Funmi Ayanbule; Narasimhaswamy S Belaguli; David H Berger
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

7.  Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening.

Authors:  Susumu Aikou; Yasukazu Ohmoto; Toshiaki Gunji; Nobuyuki Matsuhashi; Hiroshi Ohtsu; Hirona Miura; Kensuke Kubota; Yukinori Yamagata; Yasuyuki Seto; Atsushi Nakajima; James R Goldenring; Michio Kaminishi; Sachiyo Nomura
Journal:  Gastroenterology       Date:  2011-05-27       Impact factor: 22.682

8.  Expression of trefoil factors 1 and 2 in precancerous condition and gastric cancer.

Authors:  Shu-Qing Shi; Jian-Ting Cai; Jian-Ming Yang
Journal:  World J Gastroenterol       Date:  2006-05-21       Impact factor: 5.742

9.  Prognostic evaluation of oestrogen-regulated protein immunoreactivity in ductal invasive (NOS) breast cancer.

Authors:  L Nakopoulou; A C Lazaris; D Baltas; I Giannopoulou; N Kavantzas; A Tzonou
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  cDNA cloning of rat pS2 peptide and expression of trefoil peptides in acetic acid-induced colitis.

Authors:  H Itoh; M Tomita; H Uchino; T Kobayashi; H Kataoka; R Sekiya; Y Nawa
Journal:  Biochem J       Date:  1996-09-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.